Company intelligence

KymaThera

BiotechSee connections →

Recent changes

  1. Oct 6, 2026Raised $80M Series B Pulse2.com
  2. Oct 6, 2026New investor: Foresite Capital Pulse2.com
  3. Oct 6, 2026New investor: Venrock Pulse2.com
  4. Oct 6, 2026KymaThera Raises $80M For A Precision Cancer Drug Pulse story

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Oct 6, 2026Series B$80M—
VenrockunverifiedForesite CapitalunverifiedAlta Partners to advance K-1728
Pulse story

Investors

Foresite CapitalVenrock

Latest Pulse

  1. KymaThera Raises $80M For A Precision Cancer DrugKymaThera raised an $80 million Series B led by Alta Partners to advance K-1728, an oral PI3K-alpha inhibitor designed to treat breast cancer and vascular malformations while avoiding the toxicity that has limited earlier drugs in its class.→

Coverage Timeline

newest first
  1. Oct 6, 2026FUNDINGKymaThera Raises $80M For A Precision Cancer Drug$80M Series B→

All Coverage

FUNDING

KymaThera Raises $80M For A Precision Cancer Drug

Illustration for: KymaThera Raises $80M For A Precision Cancer Drug
FUNDING$80M Series B

KymaThera Raises $80M For A Precision Cancer Drug

KymaThera raised an $80 million Series B led by Alta Partners to advance K-1728, an oral PI3K-alpha inhibitor designed to treat breast cancer and vascular malformations while avoiding the toxicity that has limited earlier drugs in its class.

DEEP DIVE

Related Companies

Same sector
Scribe TherapeuticsAttovia TherapeuticsApnimedRetension PharmaceuticalsBraveheart BioEli Lilly

KymaThera FAQ

Who are KymaThera's investors?

KymaThera's investors include Foresite Capital, Venrock.

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction